Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin to Improve Liver Regeneration After Major Liver Resection
2013-004644-28Phase 2Terminated
- Sponsor
- RWTH Aachen University
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of rifaximin in hepatic disease, liver cancer and hepatic neoplasm, sponsored by RWTH Aachen University. Primary endpoints: Postoperative liver function on day 4 and Postoperative liver function on day 7. Started Mar 2014; status: terminated.
02
Drugs
rifaximin
03
Conditions
hepatic diseaseliver cancerhepatic neoplasm
Beyond the preview
Go deeper on 2013-004644-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004644-28.